{'fraction_non_alphanumeric': 0.022818791946308724, 'fraction_numerical': 0.005369127516778523, 'mean_word_length': 5.065040650406504, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
THE TREATMENT OF HIRSUTISM: EXPERIENCE WITH CYPROTERONE ACETATE AND SPIRONOLACTONE

Twenty‐three patients were treated with either cyproterone acetate (n = 14) or spirono‐ lactone (n = 12) for a period of not less than twelve months. Plasma and urinary androgen levels fall significantly with cyproterone acetate but showed little change with spironolactone. Sebum production fell in both groups as did hair diameters. The frequency of cosmetic measures used by the patients was reduced during both forms of therapy. No serious side effects were observed. However, these drugs should not be used in patients without adequate contraception because of the risk to the foetus. Further evaluation of the relative merits of the two drugs is required.